Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 1/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.36 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221191 | 1.00 | MAPT (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4456772 | 1.00 | MAPT (0.52) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4428938 | 0.92 | MAPT (0.68) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Acetylcysteine SCHEMBL4428940 | 0.92 | MAPT (0.68) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4462156 | 0.81 | TGFBR1 (0.37) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4469725 | 0.81 | NOD1 (0.38) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4461437 | 0.81 | TGFBR1 (0.37) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4459978 | 0.81 | SMN1; SMN2 (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4459983 | 0.81 | SMN1; SMN2 (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL6555886 | 0.81 | KDM4E (0.36) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1030 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124338-A1 | ANTIBACTERIAL WOUND TREATMENTS WITH CLOT-PROMOTING PROPERTIES | UNIV GEORGIA (US) | 2026-05-07 | — | — | US | claimed |
| US-12611431-B2 | Approach to sustained production and delivery of nitric oxide and S-nitrosothiols | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-28 | — | — | US | claimed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | claimed |
| EP-4709824-A2 | SUPERHYDROPHOBIC ANTIFOULING COATING COMPOSITIONS FOR RELEASING NITRIC OXIDE AND APPLICATIONS THEREOF | University of Georgia Research Foundation, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2026044058-A1 | SLIPPERY ORGANOGELS AND METHODS FOR MAKING AND USING THE SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-12533439-B2 | Antibacterial wound treatments with clot-promoting properties | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-01-27 | — | — | US | claimed |
| US-12496377-B2 | Nitric oxide releasing slippery surfaces for decreased fouling, thrombosis, and infection of medical devices | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-12-16 | — | — | US | claimed |
| WO-2025245356-A1 | NITRIC OXIDE RELEASING ARTICLES WITH ENHANCED ALBUMIN AFFINITY AND METHODS FOR MAKING AND USING THE SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025128507-A1 | NITRIC OXIDE RELEASING SPONGES AND METHODS FOR MAKING AND USING THE SAME | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025096043-A1 | NITRIC OXIDE RELEASING FILMS AND SYSTEMS | NOTA Laboratories, Inc. (US) | 2025-05-08 | — | — | WO | claimed |
| EP-0582631-B1 | Use of S-nitrosothiols for the preparation of a medicament for the relaxation of smooth muscle | BRIGHAM & WOMENS HOSPITAL (US) | 1999-12-01 | — | — | EP | claimed |
| US-5994294-A | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses | NITROMED, INC. (US) | 1999-11-30 | — | — | US | claimed |
| US-5958926-A | FOR TREATING SEXUAL DISORDERS | NITROMED, INC. (US) | 1999-09-28 | — | — | US | claimed |
| US-5932538-A | THERAPY FOR HUMAN MALE IMPOTENCY OR ERECTILE DYSFUNCTION | NITROMED, INC. (US) | 1999-08-03 | — | — | US | claimed |
| US-5648393-A | Treatment of male impotence with s-nitrosylated compounds | BRIGHAM & WOMEN'S HOSPITAL (US) | 1997-07-15 | — | — | US | claimed |
| WO-1997018000-A1 | S-NITROSO-HEMOGLOBIN AND THERAPEUTIC USES THEREOF | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1997-05-22 | — | — | WO | claimed |
| US-5385937-A | Preventing peroxide generation from mercaptan groups and endothelial injury | BRIGHAM & WOMEN'S HOSPITAL (US) | 1995-01-31 | — | — | US | claimed |
| US-5380758-A | Respiratory, gastrointestinal | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-01-10 | — | — | US | claimed |
| WO-1994016740-A1 | THE USE OF NITRIC OXIDE-DELIVERING COMPOUNDS FOR THE TREATMENT OR PREVENTION OF ALCOHOLIC LIVER INJURY | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1993012068-A1 | S-NITROSOTHIOLS AS SMOOTH MUSCLE RELAXANTS AND THERAPEUTIC USES THEREOF | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1993-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611431-B2 | Approach to sustained production and delivery of nitric oxide and S-nitrosothiols | NOS2, NOS1, PTGIS | MAPT 3371/4885KDM4E 4733/4885THRB 4168/4885 |
| US-12533439-B2 | Antibacterial wound treatments with clot-promoting properties | FGB, MGMT, F2 | MAPT 2145/4885KDM4E 2794/4885THRB 3290/4885 |
| US-20260124338-A1 | ANTIBACTERIAL WOUND TREATMENTS WITH CLOT-PROMOTING PROPERTIES | FGB, MGMT, F2 | MAPT 1852/4885KDM4E 2936/4885THRB 2110/4885 |
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | MAPT 1646/4885KDM4E 2777/4885THRB 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.